
Parry J Guilford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5868435/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	E-cadherin germline mutations in familial gastric cancer. Nature, 1998, 392, 402-405.	13.7	1,542
2	Defective myosin VIIA gene responsible for Usher syndrome type IB. Nature, 1995, 374, 60-61.	13.7	1,101
3	Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology, 2001, 121, 1348-1353.	0.6	579
4	Hereditary Diffuse Gastric Cancer Syndrome. JAMA Oncology, 2015, 1, 23.	3.4	540
5	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 2010, 47, 436-444.	1.5	495
6	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	1.5	479
7	Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 2000, 26, 16-17.	9.4	420
8	Early events in cell adhesion and polarity during epithelial-mesenchymal transition. Journal of Cell Science, 2012, 125, 4417-4422.	1.2	286
9	A non–syndromic form of neurosensory, recessive deafness maps to the pericentromeric region of chromosome 13q. Nature Genetics, 1994, 6, 24-28.	9.4	262
10	E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Human Mutation, 1999, 14, 249-255.	1.1	247
11	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	5.1	237
12	Triple gene block proteins of white clover mosaic potexvirus are required for transport. Virology, 1991, 183, 695-702.	1.1	200
13	The Y Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. American Journal of Human Genetics, 2005, 77, 1034-1043.	2.6	197
14	Hereditary Diffuse Gastric Cancer: Diagnosis and Management. Clinical Gastroenterology and Hepatology, 2006, 4, 262-275.	2.4	163
15	E-Cadherin Deficiency Initiates Gastric Signet-Ring Cell Carcinoma in Mice and Man. Cancer Research, 2009, 69, 2050-2056.	0.4	147
16	Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer, 2010, 13, 1-10.	2.7	143
17	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Human Molecular Genetics, 2006, 15, 443-451.	1.4	138
18	A human gene responsible for neurosensory, non-syndromic recessive deafness is a candidate homologue of the mouse sh-1 gene. Human Molecular Genetics, 1994, 3, 989-993.	1.4	134

Parry J Guilford

#	Article	IF	CITATIONS
19	Germline E-cadherin gene mutations. Cancer, 2001, 92, 181-187.	2.0	131
20	A Multigene Urine Test for the Detection and Stratification of Bladder Cancer in Patients Presenting with Hematuria. Journal of Urology, 2012, 188, 741-747.	0.2	128
21	Destabilized Adhesion in the Gastric Proliferative Zone and c-Src Kinase Activation Mark the Development of Early Diffuse Gastric Cancer. Cancer Research, 2007, 67, 2480-2489.	0.4	114
22	Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer. Clinical Cancer Research, 2007, 13, 498-507.	3.2	114
23	E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer, 2014, 14, 552.	1.1	108
24	E-cadherin downregulation in cancer: fuel on the fire?. Trends in Molecular Medicine, 1999, 5, 172-177.	2.6	104
25	Secreted CXCL1 Is a Potential Mediator and Marker of the Tumor Invasion of Bladder Cancer. Clinical Cancer Research, 2008, 14, 2579-2587.	3.2	95
26	Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 531.e15-531.e22.	0.8	94
27	A gene responsible for a dominant form of neurosensory non-syndromic deafness maps to the NSRD1 recessive deafness gene interval. Human Molecular Genetics, 1994, 3, 2219-2222.	1.4	93
28	Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene, 2002, 21, 8192-8195.	2.6	91
29	Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer. Clinical Cancer Research, 2004, 10, 2784-2789.	3.2	83
30	Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. Journal of Urology, 2017, 197, 1419-1426.	0.2	82
31	Hereditary diffuse gastric cancer: A manifestation of lost cell polarity. Cancer Science, 2009, 100, 1151-1157.	1.7	78
32	Development of a Multiplex RNA Urine Test for the Detection and Stratification of Transitional Cell Carcinoma of the Bladder. Clinical Cancer Research, 2008, 14, 742-749.	3.2	74
33	Clinical spectrum and pleiotropic nature of <i>CDH1</i> germline mutations. Journal of Medical Genetics, 2019, 56, 199-208.	1.5	74
34	Novel germlineCDH1mutations in hereditary diffuse gastric cancer families. Human Mutation, 2002, 19, 518-525.	1.1	63
35	Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clinical Cancer Research, 2008, 14, 5173-5180.	3.2	62
36	A Comparison of Real-Time and Endpoint Cell Viability Assays for Improved Synthetic Lethal Drug Validation. Journal of Biomolecular Screening, 2015, 20, 1286-1293.	2.6	51

PARRY J GUILFORD

#	Article	IF	CITATIONS
37	P21-Activated Kinase 1: A New Molecular Marker for Intravesical Recurrence After Transurethral Resection of Bladder Cancer. Journal of Urology, 2007, 178, 1073-1079.	0.2	44
38	Hereditary gastric cancer: what's new? Update 2013–2018. Familial Cancer, 2019, 18, 363-367.	0.9	44
39	Expression of Krüppel-like factor 5 in human gastric carcinomas. Journal of Cancer Research and Clinical Oncology, 2007, 134, 163-167.	1.2	42
40	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 492-499.	0.8	42
41	Epigenetic silencing in nonâ€neoplastic epithelia identifies Eâ€cadherin (<i>CDH1</i>) as a target for chemoprevention of lobular neoplasia. Journal of Pathology, 2009, 218, 265-272.	2.1	41
42	Analysis of the <i>DND1</i> gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes and Cancer, 2008, 47, 247-252.	1.5	37
43	A short guide to hereditary diffuse gastric cancer. Hereditary Cancer in Clinical Practice, 2007, 5, 183.	0.6	36
44	Hereditary diffuse gastric cancer. Advances in Cancer Research, 2001, 83, 55-65.	1.9	35
45	Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand MÄori. Familial Cancer, 2019, 18, 83-90.	0.9	33
46	Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer. BMC Cancer, 2017, 17, 228.	1.1	32
47	Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells. Molecular Cancer Therapeutics, 2015, 14, 1213-1223.	1.9	30
48	Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Research, 2009, 11, R45.	2.2	28
49	A YAC Contig and an EST Map in the Pericentromeric Region of Chromosome 13 Surrounding the Loci for Neurosensory Nonsyndromic Deafness (DFNB1 and DFNA3) and Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C). Genomics, 1995, 29, 163-169.	1.3	25
50	E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. Gastric Cancer, 2019, 22, 273-286.	2.7	24
51	Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells. Cancers, 2019, 11, 1359.	1.7	22
52	Cohesin mutations are synthetic lethal with stimulation of WNT signaling. ELife, 2020, 9, .	2.8	22
53	N-Terminal E-Cadherin Peptides Act as Decoy Receptors for Listeria monocytogenes. Infection and Immunity, 2003, 71, 1580-1583.	1.0	19
54	Comparison of Roche Cell-Free DNA collection Tubes to Streck Cell-Free DNA BCT s for sample stability using healthy volunteers. Practical Laboratory Medicine, 2019, 16, e00125.	0.6	18

PARRY J GUILFORD

#	Article	IF	CITATIONS
55	Organization and interviral homologies of the coat protein gene of white clover mosaic virus. Virology, 1988, 162, 459-465.	1.1	17
56	Mutation and replacement of the 16-kDa protein gene IN RNA-1 of tobacco rattle virus. Virology, 1991, 182, 607-614.	1.1	16
57	Risk of stomach cancer in Aotearoa/New Zealand: A MÄori population based case-control study. PLoS ONE, 2017, 12, e0181581.	1.1	15
58	A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: A case control study in an Italian population. BMC Cancer, 2008, 8, 138.	1.1	13
59	Hereditary diffuse gastric cancer and lost cell polarity: a short path to cancer. Future Oncology, 2008, 4, 229-239.	1.1	13
60	A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells. Scientific Reports, 2019, 9, 12511.	1.6	13
61	Identification of c.1531C>T Pathogenic Variant in the CDH1 Gene as a Novel Germline Mutation of Hereditary Diffuse Gastric Cancer. International Journal of Molecular Sciences, 2019, 20, 4980.	1.8	12
62	E-cadherin signal sequence disruption: a novel mechanism underlying hereditary cancer. Molecular Cancer, 2018, 17, 112.	7.9	11
63	Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. Carcinogenesis, 2020, 41, 1507-1517.	1.3	11
64	Modelling hereditary diffuse gastric cancer initiation using transgenic mouseâ€derived gastric organoids and singleâ€cell sequencing. Journal of Pathology, 2021, 254, 254-264.	2.1	11
65	Oligonucleotide array outperforms SNP array on formalin-fixed paraffin-embedded clinical samples. Cancer Genetics and Cytogenetics, 2010, 198, 1-6.	1.0	10
66	E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors. Cancers, 2022, 14, 175.	1.7	8
67	Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models. Bioinformatics, 2007, 23, 732-738.	1.8	7
68	Sequence Characterization of a Newly Identified Human α-Tubulin Gene (TUBA2). Genomics, 1998, 47, 125-130.	1.3	6
69	Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking. Cancers, 2022, 14, 102.	1.7	6
70	Culture, law, ethics, and social implications: Is society ready for advanced. Australasian Medical Journal, 2014, 7, 200-202.	0.1	5
71	E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib. Cancers, 2022, 14, 1609.	1.7	4
72	Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer. Journal of Medicinal Chemistry, 2021, 64, 18114-18142.	2.9	4

5

Parry J Guilford

#	Article	IF	CITATIONS
73	E-cadherin unlikely to be a common ?low penetrance? gene for colorectal cancer. American Journal of Medical Genetics Part A, 1999, 84, 169-171.	2.4	3
74	Updated perspective and directions on hereditary diffuse gastric cancer. , 2021, , 217-258.		1
75	An estimate of limited duration cancer prevalence in New Zealand using 'big' data. New Zealand Medical Journal, 2020, 133, 49-62.	0.5	1
76	Gastric Cancer: Inherited Predisposition. , 2002, , 253-258.		0
77	Molecular Mechanisms of Hereditary Diffuse Gastric Cancer Initiation and Progression. , 2013, , 51-76.		Ο
78	Where to from here? Posthumous healthcare data, digital e(lectronic)-mortality and New Zealand's healthcare future. New Zealand Medical Journal, 2017, 130, 64-70.	0.5	0